Michaela Feuring-Buske
Overview
Explore the profile of Michaela Feuring-Buske including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
1299
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Heuser M, Freeman S, Ossenkoppele G, Buccisano F, Hourigan C, Ngai L, et al.
Blood
. 2021 Nov;
138(26):2753-2767.
PMID: 34724563
Measurable residual disease (MRD) is an important biomarker in acute myeloid leukemia (AML) that is used for prognostic, predictive, monitoring, and efficacy-response assessments. The European LeukemiaNet (ELN) MRD Working Party...
2.
Kreissl S, Goergen H, Buehnen I, Kobe C, Moccia A, Greil R, et al.
Lancet Haematol
. 2021 May;
8(6):e398-e409.
PMID: 34048679
Background: The German Hodgkin Study Group's HD18 trial established the safety and efficacy of PET-guided eBEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone in escalated doses) for the treatment...
3.
Bamezai S, Demir D, Pulikkottil A, Ciccarone F, Fischbein E, Sinha A, et al.
Leukemia
. 2020 May;
35(2):389-403.
PMID: 32409690
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological cancer characterized by skewed epigenetic patterns, raising the possibility of therapeutically targeting epigenetic factors in this disease. Here we report that...
4.
Hanekamp D, Snel A, Kelder A, Scholten W, Khan N, Metzner M, et al.
Br J Haematol
. 2020 Apr;
190(6):891-900.
PMID: 32239670
Leukaemic stem cells (LSC) have been experimentally defined as the leukaemia-propagating population and are thought to be the cellular reservoir of relapse in acute myeloid leukaemia (AML). Therefore, LSC measurements...
5.
Vegi N, Chakrabortty S, Zegota M, Kuan S, Stumper A, Rawat V, et al.
Sci Rep
. 2020 Jan;
10(1):371.
PMID: 31941913
Acute myeloid leukemia (AML) is characterized by relapse and treatment resistance in a major fraction of patients, underlining the need of innovative AML targeting therapies. Here we analysed the therapeutic...
6.
Thoene S, Mandal T, Vegi N, Quintanilla-Martinez L, Rosler R, Wiese S, et al.
Blood Adv
. 2019 Nov;
3(22):3729-3739.
PMID: 31770439
Acute erythroid leukemia (AEL) is a rare and aggressive form of acute leukemia, the biology of which remains poorly understood. Here we demonstrate that the ParaHox gene CDX4 is expressed...
7.
Feder K, Edmaier-Schroger K, Rawat V, Kirsten N, Metzeler K, Kraus J, et al.
Leukemia
. 2019 Nov;
34(4):1027-1037.
PMID: 31758089
Acute myeloid leukemia (AML) is the most common acute leukemia in adults and is propagated by leukemic stem cells (LSCs), often characterized by deregulated Wnt signaling. We previously showed that...
8.
Rawat V, Gotze M, Rasalkar A, Vegi N, Ihme S, Thoene S, et al.
Haematologica
. 2019 Sep;
105(6):e285-e289.
PMID: 31558674
No abstract available.
9.
Boll B, Plutschow A, Burkle C, Atta J, Pfreundschuh M, Feuring-Buske M, et al.
Br J Haematol
. 2018 Dec;
185(1):42-52.
PMID: 30592027
About 30% of all Hodgkin lymphoma (HL) patients are ≥60 years old. As lenalidomide has promising single agent activity in multiple relapsed HL, we replaced bleomycin in ABVD with lenalidomide...
10.
Borchmann P, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer D, et al.
Lancet
. 2017 Oct;
390(10114):2790-2802.
PMID: 29061295
Background: The intensive polychemotherapy regimen eBEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone in escalated doses) is very active in patients with advanced-stage Hodgkin's lymphoma, albeit at the expense...